ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,262.75
-0.15%
Dow Jones
38,299.67
-1.00%
Gold vs US Dollar
2,342.66
0.66%
Brent Oil
78.355
-3.03%
Bitcoin
69,142.80
2.05%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. LAVA Therapeutics NV (LVTX)

  7. LAVA Therapeutics NV (LVTX) News

LAVA Therapeutics NV (LVTX)

LAVA Therapeutics NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LVTX
DateTimeSourceHeadlineSymbolCompany
21/05/202421:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LVTXLAVA Therapeutics NV
25/01/202413:07Dow Jones NewsLava Therapeutics Shares Rise as Drug Set for Test With Merck's KeytrudaNASDAQ:LVTXLAVA Therapeutics NV
16/11/202321:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LVTXLAVA Therapeutics NV
06/09/202312:11GlobeNewswire Inc.LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:LVTXLAVA Therapeutics NV
22/08/202321:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LVTXLAVA Therapeutics NV
22/08/202312:00GlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
15/08/202311:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LVTXLAVA Therapeutics NV
14/08/202312:00GlobeNewswire Inc.LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual ConferenceNASDAQ:LVTXLAVA Therapeutics NV
15/06/202321:51Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
14/06/202314:00GlobeNewswire Inc.LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash RunwayNASDAQ:LVTXLAVA Therapeutics NV
08/06/202321:06Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
08/06/202312:00GlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
06/06/202311:02Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LVTXLAVA Therapeutics NV
05/06/202323:31Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:LVTXLAVA Therapeutics NV
02/06/202300:38Dow Jones NewsStocks to Watch: Lululemon, Lava Therapeutics, Tilly's, OncorusNASDAQ:LVTXLAVA Therapeutics NV
01/06/202321:20GlobeNewswire Inc.LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical DevelopmentNASDAQ:LVTXLAVA Therapeutics NV
01/06/202313:09GlobeNewswire Inc.LAVA Therapeutics to Participate in the Jefferies Healthcare ConferenceNASDAQ:LVTXLAVA Therapeutics NV
30/05/202322:28GlobeNewswire Inc.LAVA Announces Annual Meeting of ShareholdersNASDAQ:LVTXLAVA Therapeutics NV
24/04/202321:07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
12/04/202311:03Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
11/04/202312:00GlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
09/03/202313:05GlobeNewswire Inc.LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of DirectorsNASDAQ:LVTXLAVA Therapeutics NV
16/02/202312:06Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
16/02/202312:00GlobeNewswire Inc.LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU SymposiumNASDAQ:LVTXLAVA Therapeutics NV
09/02/202312:00GlobeNewswire Inc.LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma ConferenceNASDAQ:LVTXLAVA Therapeutics NV
06/02/202312:07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
06/02/202312:00GlobeNewswire Inc.LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical OfficerNASDAQ:LVTXLAVA Therapeutics NV
23/01/202312:00GlobeNewswire Inc.LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU SymposiumNASDAQ:LVTXLAVA Therapeutics NV
06/01/202318:07GlobeNewswire Inc.LAVA Therapeutics Announces Appointment of New Directors to the BoardNASDAQ:LVTXLAVA Therapeutics NV
03/01/202312:00GlobeNewswire Inc.LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:LVTXLAVA Therapeutics NV
 Showing the most relevant articles for your search:NASDAQ:LVTX

Your Recent History

LSE
RG58
Clydesdle Bk.28
MRTX
LTBETH
Litbinex Coin
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved